Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 11, 2022 16:05 ET | Source: Mustang Bio, Inc.

Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
July 27, 2022 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency

WORCESTER, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
June 22, 2022 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia

WORCESTER, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
June 13, 2022 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy

94% overall response rate and 78% complete response rate in patients with FL, including complete response in a patient previously treated with CD19-targeted CAR T therapy 100% overall response rate...
May 19, 2022 08:45 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107

All 23 treated patients are alive at 2.6-year median follow-up without evidence of malignant transformation Data representing largest cohort of infants with XSCID treated with gene therapy presented...
May 12, 2022 16:05 ET | Source: Mustang Bio, Inc.

Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
May 12, 2022 10:38 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress

Favorable safety profile, high overall response and complete response rates, and CAR T persistence observed in patients with relapsed or refractory follicular lymphoma Data to be presented by Fred...
May 03, 2022 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting

Data represent largest cohort of infants with XSCID, also known as bubble boy disease, who received lentiviral gene therapy with the longest follow-up to date Seventeen of 18 patients with follow-up...
April 25, 2022 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Very favorable safety profile suitable for outpatient treatment, high complete response rate and strong durability observed, including patients with Waldenstrom macroglobulinemia and those who...
April 21, 2022 08:30 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations

WORCESTER, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...